PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Disease ReportsChronic hepatitis c
MeSH D019698 - chronic hepatitis c
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D006526:Hepatitis c
$
Success rate
D006521:Chronic hepatitis
0 Companies
0 Drugs
Success rate
D019698: 
Chronic hepatitis c
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
TevaRibavirin Ribavirin  2004-10-04   
Ribavirin Ribavirin Teva  2009-03-31   
Ribavirin Ribavirin Teva Pharma B.V  2009-07-01   
Sofosbuvir Sofosbuvir  2022-01-27   
MylanRibavirin Ribavirin Mylan (previously Ribavirin Three Rivers)  2010-06-10   
Johnson & JohnsonTelaprevir Incivo  2011-09-19   
Simeprevir Olysio 2025-05-19 2013-11-22   
RocheRibavirin Copegus  2002-12-03   
Ribavirin, Peginterferon alfa-2a Pegasys Copegus  2004-06-04   
Interferon alfa-2a Roferon-A  1986-06-04   
SandozRibavirin Ribavirin  2006-10-03   
AbbVieDasabuvir Exviera  2015-01-14   
Glecaprevir, Pibrentasvir Maviret  2017-07-26   
Ritonavir, Ombitasvir, Paritaprevir Technivie 2024-08-25 2015-07-24   
Ritonavir, Dasabuvir, Ombitasvir, Paritaprevir Viekira 2024-08-25 2014-12-19 $16 M Q2/19-Q1/20 
Ritonavir, Ombitasvir, Paritaprevir Viekirax  2015-01-14   
Bausch Health CompaniesRibavirin Virazole  1985-12-31   
Merck & CoRibavirin Cotronak  1999-05-07   
Interferon alfa-2b Intron A  1986-06-04   
Interferon alfa-2b IntronA  2000-03-09   
Peginterferon alfa-2b PegIntron  2001-01-19   
Ribavirin, Peginterferon alfa-2b PegIntron/ Rebetol Combo Pack  2008-06-13   
Ribavirin Rebetol  1998-06-03   
Boceprevir Victrelis 2024-12-22 2011-05-13   
Interferon alfa-2b Viraferon  2000-03-09   
Peginterferon alfa-2b ViraferonPeg  2000-05-28   
Elbasvir, Grazoprevir Zepatier 2029-07-24 2016-01-28 $167 M Y2020 
Aurobindo PharmaRibavirin Ribavirin  2009-09-17   
Zydus TherapeuticsRibavirin Ribavirin  2005-12-05   
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
73%
32/44
Phase 2
69%
41/59
Phase 3
74%
68/92
Approved: 38Overall Success rate: 37%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Teva
1
2
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use